New antibody treatment may shield leukemia patients from deadly infections

NCT ID NCT04502030

Completed Disease control Sponsor: Octapharma Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times

Summary

This study tested whether Panzyga, an antibody treatment, can prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. About 247 adults with CLL received either Panzyga or a placebo. The goal was to see if Panzyga reduces major infections like pneumonia or bloodstream infections. Results could help manage infection risk in these patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Octapharma Research Site

St. Petersburg, Florida, 33709, United States
Octapharma Research Site

Columbus, Georgia, 31904, United States
Octapharma Research Site

Macon, Georgia, 31201, United States
Octapharma Research Site

New Orleans, Louisiana, 70112, United States
Octapharma Research Site

Baltimore, Maryland, 21201, United States
Octapharma Research Site

Baltimore, Maryland, 21205, United States
Octapharma Research Site

Detroit, Michigan, 48093, United States
Octapharma Research Site

Rochester, Minnesota, 55902, United States
Octapharma Research Site

Buffalo, New York, 14260, United States
Octapharma Research Site

New York, New York, 10032, United States
Octapharma Research Site

New York, New York, 10065, United States
Octapharma Research Site

Shirley, New York, 11967, United States
Octapharma Research Site

Durham, North Carolina, 27710, United States
Octapharma Research Site

Charleston, South Carolina, 29414, United States
Octapharma Research Site

Houston, Texas, 77090, United States
Octapharma Research Site

Brno, 625 00, Czechia
Octapharma Research Site

Hradec Králové, 500 05, Czechia
Octapharma Research Site

Ostrava, 70852, Czechia
Octapharma Research Site

Aalborg, 9000, Denmark
Octapharma Research Site

Herning, 7400, Denmark
Octapharma Research Site

Roskilde, 4000, Denmark
Octapharma Research Site

Dortmund, 44263, Germany
Octapharma Research Site

Frankfurt, 15236, Germany
Octapharma Research Site

Kiel, 24105, Germany
Octapharma Research Site

Marburg, 35037, Germany
Octapharma Research Site

Athens, 10676, Greece
Octapharma Research Site

Athens, 11526, Greece
Octapharma Research Site

Athens, 12462, Greece
Octapharma Research Site

Ioannina, 45500, Greece
Octapharma Research Site

Pátrai, 26500, Greece
Octapharma Research Site

Thessaloniki, 57010, Greece
Octapharma Research Site

Budapest, 1088, Hungary
Octapharma Research Site

Debrecen, 4032, Hungary
Octapharma Research Site

Győr, 9023, Hungary
Octapharma Research Site

Kaposvár, 7400, Hungary
Octapharma Research Site

Nyíregyháza, 4400, Hungary
Octapharma Research Site

Haifa, 3109601, Israel
Octapharma Research Site

Haifa, 34362, Israel
Octapharma Research Site

Petah Tikva, 49100, Israel
Octapharma Research Site

Castelfranco Veneto, 31033, Italy
Octapharma Research Site

Milan, 20132, Italy
Octapharma Research Site

Milan, 20162, Italy
Octapharma Research Site

Modena, 41124, Italy
Octapharma Research Site

Orbassano, 10043, Italy
Octapharma Research Site

Padova, 35129, Italy
Octapharma Research Site

Pescara, 65124, Italy
Octapharma Research Site

Reggio Calabria, 89133, Italy
Octapharma Research Site

Rome, 00161, Italy
Octapharma Research Site

Torino, 10126, Italy
Octapharma Research Site

Bialystok, 15-732, Poland
Octapharma Research Site

Bydgoszcz, 85-065, Poland
Octapharma Research Site

Gdansk, 80-214, Poland
Octapharma Research Site

Gdansk, 80-219, Poland
Octapharma Research Site

Gdynia, 81-519, Poland
Octapharma Research Site

Katowice, 40-519, Poland
Octapharma Research Site

Legnica, 59-220, Poland
Octapharma Research Site

Lodz, 93-513, Poland
Octapharma Research Site

Torun, 87-100, Poland
Octapharma Research Site

Warsaw, 02-776, Poland
Octapharma Research Site

Wroclaw, 50-367, Poland
Octapharma Research Site

Barnaul, 656024, Russia
Octapharma Research Site

Kemerovo, 650066, Russia
Octapharma Research Site

Moscow, 115478, Russia
Octapharma Research Site

Moscow, 125284, Russia
Octapharma Research Site

Nizhny Novgorod, 603126, Russia
Octapharma Research Site

Novosibirsk, 630051, Russia
Octapharma Research Site

Petrozavodsk, 185019, Russia
Octapharma Research Site

Rostov-on-Don, 344037, Russia
Octapharma Research Site

Saint Petersburg, 191024, Russia
Octapharma Research Site

Samara, 443079, Russia
Octapharma Research Site

Tomsk, 634063, Russia
Octapharma Research Site

Tula, 300053, Russia
Octapharma Research Site

Ufa, 450008, Russia
Octapharma Research Site

Yekaterinburg, 620102, Russia
Octapharma Research Site

Madrid, 28034, Spain
Octapharma Research Site

Madrid, 28040, Spain
Octapharma Research Site

Madrid, 28046, Spain
Octapharma Research Site

Oviedo, 33011, Spain
Octapharma Research Site

Santander, 39008, Spain
Octapharma Research Site

Antalya, 7050, Turkey (Türkiye)
Octapharma Research Site

Cebeci/Ankara, 65900, Turkey (Türkiye)
Octapharma Research Site

Fatih/Istanbul, 34093, Turkey (Türkiye)
Octapharma Research Site

Kazimdirik, 35100, Turkey (Türkiye)
Octapharma Research Site

Melikgazi/Kayseri, 38039, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.

CHRONIC LYMPHOCYTIC LEUKEMIA HYPOGAMMAGLOBULINEMIA